Gsa Capital Partners LLP Day One Biopharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 63,546 shares of DAWN stock, worth $417,497. This represents 0.03% of its overall portfolio holdings.
Number of Shares
63,546
Previous 43,703
45.4%
Holding current value
$417,497
Previous $347,000
19.02%
% of portfolio
0.03%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding DAWN
# of Institutions
197Shares Held
76.8MCall Options Held
138KPut Options Held
208K-
Atlas Venture Life Science Advisors, LLC6.43MShares$42.2 Million14.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$39 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$37.8 Million0.95% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$29.8 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.06MShares$26.7 Million0.14% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $483M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...